3-[(3-sulfanylbutanoyl)oxy]-2,2-bis{[(3-sulfanylbutanoyl)oxy]methyl}propyl 3-sulfanylbutanoate

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

16 Feb - 10 Mar 2009

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

guideline study with acceptable restrictions

Remarks:

It should be noted that there are certain limitations of the LLNA for surfactant type chemicals. Based on the physicochemical properties, PE1 is not considered as a surface-active substance but it is a borderline case and could cause a false-positive result in the LLNA. No analytical purity is given.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2009

Report date:

2009

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Remarks:

THE DEPARTMENT OF HEALTH OF THE GOVERNMENT OF THE UNITED KINGDOM

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3R)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2-({[(3R)-3-sulfanylbutanoyl]oxy}methyl)-2-({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3S)-3-sulfanylbutanoate

EC Number:

700-255-4

Cas Number:

31775-89-0

Molecular formula:

C21H36O8S4

IUPAC Name:

3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3R)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3R)-3-sulfanylbutanoyl]oxy}-2-({[(3R)-3-sulfanylbutanoyl]oxy}methyl)-2-({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3R)-3-sulfanylbutanoate; 3-{[(3S)-3-sulfanylbutanoyl]oxy}-2,2-bis({[(3S)-3-sulfanylbutanoyl]oxy}methyl)propyl (3S)-3-sulfanylbutanoate

In vivo test system

Test animals

Species:

mouse

Strain:

other: CBA/Ca (CBA/CaOlaHsd)

Sex:

female

Details on test animals and environmental conditions:

TEST ANIMALS
- Source: Harlan Laboratories UK Limited, Bicester, Oxon, UK.
- Age at study initiation: 8-12 weeks old
- Weight at study initiation: 15-23 g
- Housing: individually housed in suspended solid-floor polypropylene cages furnished with softwood woodflakes
- Diet: 2014 Teklad Global Rodent diet supplied by Harlan Teklad, Blackthorn, Bicester, Oxon, UK; ad libitum
- Water: tap water; ad libitium
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-25
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12

Study design: in vivo (LLNA)

Vehicle:

acetone/olive oil (4:1 v/v)

Concentration:

100% (undiluted), 50% and 25% v/v

No. of animals per dose:

4

Details on study design:

RANGE FINDING TESTS:
One mouse was treated by daily application of 25 µL of the undiluted test substance to the dorsal surface of each ear for three consecutive days. No signs of systemic toxicity were noted (see table 1). Based on this information, the undiluted test substance and the test substance at concentrations of 50% and 25% v/v in acetone/olive oil 4:1 were selected for the main test.

MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: ³H-methyl thymidine incorporation determined by beta-scintillation
- Criteria used to consider a positive response: The test substance will be regarded as a sensitiser if at least one concentration of the test substance results in a threefold or greater increase in ³HTdR incorporation compared to control values.

TREATMENT PREPARATION AND ADMINISTRATION:
25 μL of the test substance was applied to the entire dorsal surface of each ear of each mouse for three consecutive days (Day 1-3). Local irritation reactions were assessed. On Day 6 an injection of 250 μL phosphate buffered saline (PBS) containing 20 µCi ³H-methyl thymidine (³HTdR; 80 µCi/mL, specific activitiy 2.0. Ci/mmol) was made into the tail vein of each experimental mouse. 5 h later, all mice were sacrificed and the draining auricular lymph nodes were excised into PBS and pooled for each experimental group. A single cell suspension of pooled lymph node cells was prepared by gentle mechanical disaggregation through a 200-mesh stainless stell gauze. The lymph node cells were rinsed through a gauze with 4 mL of PBS into a petri dish. The lymph node cell suspension was transferred to centrifuge tube. The petri dish was washed with an additional 5 mL of PBS to remove all remaining lymph node cells and these were added to the centrifuge tube. The pooled lymph node cells were pelleted at 1400 rpm (approximately 190 g) for 10 min. The pellet was resuspended in 10 mL of PBS and re-pelleted. To precipitate out the radioactive material, the pellet was precipitated with 5% trichloroacetic acid at 4 °C for 18 h. ³HTdR incorporation was measured by beta-scintillation counting. The number of radioactive disintegrations per minute was then measured using the Beckman LS6500 scintillation system (Beckman Instruments Inc, Fullerton, CA).

Positive control substance(s):

hexyl cinnamic aldehyde (CAS No 101-86-0)

Results and discussion

Positive control results:

The positive control substance showed a stimulation index of 6.55 (reliability check: historic positive control data, October 2008, project number:0039/1057).

In vivo (LLNA)

Results

Results 1

Key result

Parameter:

SI

Value:

22.52

Test group / Remarks:

25% (v/v)

Results 2

Key result

Parameter:

SI

Value:

25.71

Test group / Remarks:

50% (v/v)

Results 3

Key result

Parameter:

SI

Value:

23.11

Test group / Remarks:

100%

Cellular proliferation data / Observations:

CELLULAR PROLIFERATION DATA
The radioactive disintegrations per minute (dpm) are given in Table 2

DETAILS ON STIMULATION INDEX CALCULATION
A stimulation index of greater than 3 was recorded for the undiluted test material and the test material at concentrations of 50% and 25% v/v in acetone/olive oil 4: 1.

EC3 CALCULATION
No EC3 value was established, since no conventional dose-response relationship was observed.

CLINICAL OBSERVATIONS:
There were no deaths. No signs of systemic toxicity were noted in the test or control animals during the test.

BODY WEIGHTS
Bodyweight changes of the test animals between Day 1 and Day 6 were comparable to those observed in the corresponding control group animals over the same period.

Any other information on results incl. tables

Table 1: Clinical observations, Body weight and mortality data – preliminary screening test

Concentration	Animal Number	Bodyweight (g)		Day
				1		2		3		4	5	6
		Day 1	Day 6	Pre-Dose	Post Dose	Pre-Dose	Post Dose	Pre-Dose	Post Dose
100%	S-1	17	19	0	0	0	0	0	0	0	0	0

0= No signs of systemic toxicity

Table 2: Disintegrations per Minute, Disintegrations per Minute/Node and Stimulation Index (SI)

Concentration (%v/v) in acetone/olive oil 4:1	dpm	dpm/Node^a	SI^b	Result
Vehicle	6889.00	861.13	na	na
25	155117.80	19389.73	22.52	Positive
50	177120.30	22140.04	25.71	Positive
100	159191.00	19898.88	23.11	Positive

dpm= Disintegrations per minute

a= Disintegrations per minute/node obtained by dividing the disintegrations per minute value by 8 (total number of lymph nodes)

b= Stimulation Index of 3.0 or greater indicates a positive result

na= Not applicable

Table 3: Individual clinical observations and mortality data

Concentration (% v/v) in acetone/olive oil 4:1	Animal Number	Day 1		Day 2		Day 3		Day 4	Day 5	Day 6
		Pre-Dose	Post Dose	Pre-Dose	Post Dose	Pre-Dose	Post Dose
Vehicle	1-1	0	0	0	0	0	0	0	0	0
	1-2	0	0	0	0	0	0	0	0	0
	1-3	0	0	0	0	0	0	0	0	0
	1-4	0	0	0	0	0	0	0	0	0
25	2-1	0	0	0	0	0	0	0	0	0
	2-2	0	0	0	0	0	0	0	0	0
	2-3	0	0	0	0	0	0	0	0	0
	2-4	0	0	0	0	0	0	0	0	0
50	3-1	0	0	0	0	0	0	0	0	0
	3-2	0	0	0	0	0	0	0	0	0
	3-3	0	0	0	0	0	0	0	0	0
	3-4	0	0	0	0	0	0	0	0	0
100	4-1	0	0	0	0	0	0	0	0	0
	4-2	0	0	0	0	0	0	0	0	0
	4-3	0	0	0	0	0	0	0	0	0
	4-4	0	0	0	0	0	0	0	0	0

0= No signs of systemic toxicity

Table 4: Individual body weights and body weight changes

Concentration (% v/v) in acetone/olive oil 4:1	Animal Number	Body weight (g)		Body weight Change (g)
		Day 1	Day 6
Vehicle	1-1	18	17	-1
	1-2	18	18	0
	1-3	18	17	-1
	1-4	18	18	0
25	2-1	20	19	-1
	2-2	18	18	0
	2-3	19	19	0
	2-4	18	19	1
50	3-1	17	17	0
	3-2	17	18	1
	3-3	17	17	0
	3-4	17	17	0
100	4-1	17	16	-1
	4-2	20	19	-1
	4-3	20	19	-1
	4-4	17	17	0

 

Applicant's summary and conclusion

Interpretation of results:

other: Skin Sens Cat 1B is required according to Regulation (EC) No 1272/2008

Conclusions:

Under the conditions of the local lymph node assay, the test substance revealed a SI ≥ 3 at concentrations of 25, 50 and 100%. Therefore, the test substance is considered as weak sensitiser.